MicroRNA‑320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulin‑like growth factor 1 receptor

  • Authors:
    • Jinghong Guan
    • Yidong Zhou
    • Feng Mao
    • Yan Lin
    • Songjie Shen
    • Yanna Zhang
    • Qiang Sun
  • View Affiliations

  • Published online on: June 20, 2018     https://doi.org/10.3892/or.2018.6517
  • Pages: 849-858
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study was performed to investigate the biological functions of microRNA‑320a in human breast cancer and the underlying mechanisms. MicroRNA‑320a expression was downregulated in human breast cancer, compared with the normal control. Overexpression of microRNA‑320a induced apoptosis, and inhibited cell viability and invasion in MDA‑MB‑231cells while downregulation of microRNA‑320a reduced apoptosis, and increased cell viability and invasion in MDA‑MB‑231 cells. Then, overexpression of microRNA‑320a suppressed insulin‑like growth factor 1 receptor (IGF‑1R), p‑AKt and cyclin D1 protein expression in MDA‑MB‑231cells. In addition, the downregulation of microRNA‑320a induced IGF‑1R, p‑Akt and cyclin D1 protein expression in MDA‑MB‑231cells. Furthermore, the IGF‑1R inhibitor increased the effects of microRNA‑320a on the apoptosis of MDA‑MB‑231 cells. The p‑Akt inhibitor (MK 2206 dihydrochloride, 2.5 nM) increased the effects of microRNA‑320a on the apoptosis of MDA‑MB‑231 cells. These results revealed that microRNA‑320a suppresses tumor cell growth and invasion of human breast cancer by targeting IGF‑1R.

References

1 

Chirico A, D'Aiuto G, Penon A, Mallia L, DE Laurentiis M, Lucidi F, Botti G and Giordano A: Self-efficacy for coping with cancer enhances the effect of reiki treatments during the pre-surgery phase of breast cancer patients. Anticancer Res. 37:3657–3665. 2017.PubMed/NCBI

2 

Pu Z, Zhang X, Chen Q, Yuan X and Xie H: Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells. Oncol Rep. 33:2420–2428. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Gokal K, Wallis D, Ahmed S, Boiangiu I, Kancherla K and Munir F: Effects of a self-managed home-based walking intervention on psychosocial health outcomes for breast cancer patients receiving chemotherapy: A randomised controlled trial. Support Care Cancer. 24:1139–1166. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Zhu H, Dai M, Chen X, Chen X, Qin S and Dai S: Integrated analysis of the potential roles of miRNAmRNA networks in triple negative breast cancer. Mol Med Rep. 16:1139–1146. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Tanaka H, Hazama S, Iida M, Tsunedomi R, Takenouchi H, Nakajima M, Tokumitsu Y, Kanekiyo S, Shindo Y, Tomochika S, et al: miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. Cancer Sci. 108:2229–2238. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Murphy JP and Pinto DM: Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. Proteomics. 10:1847–1860. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Kucab JE and Dunn SE: Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis. 17:41–47. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT and Boerman OC: ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 51:1565–1572. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M and Hadji P: Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: Results of the ProBONE II substudy. Osteoporos Int. 26:353–360. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, et al: Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 124:5411–5423. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Danza K, Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R and Tommasi S: TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget. 8:50715–50723. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Piperigkou Z, Franchi M, Gotte M and Karamanos NK: Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer. Matrix Biol. 64:94–111. 2017. View Article : Google Scholar : PubMed/NCBI

13 

Yu J, Wang JG, Zhang L, Yang HP, Wang L, Ding D, Chen Q, Yang WL, Ren KH, Zhou DM, et al: MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin. Oncotarget. 7:38612–38625. 2016.PubMed/NCBI

14 

Ren JG, Seth P, Ye H, Guo K, Hanai JI, Husain Z and Sukhatme VP: Citrate suppresses tumor growth in multiple models through inhibition of glycolysis, the tricarboxylic acid cycle and the IGF-1R pathway. Sci Rep. 7:45372017. View Article : Google Scholar : PubMed/NCBI

15 

Li ZH, Xiong QY, Xu L, Duan P, Yang QO, Zhou P and Tu JH: miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway. Oncotarget. 8:32566–32575. 2017.PubMed/NCBI

16 

Guo T, Feng Y, Liu Q, Yang X, Jiang T, Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R. Tumour Biol. 35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Lin Y, Deng W, Pang J, Kemper T, Hu J, Yin J, Zhang J and Lu M: The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy. Cell Microbiol. 19:2017. View Article : Google Scholar

18 

Ma Y, Fu S, Lu L and Wang X: Role of androgen receptor on cyclic mechanical stretch-regulated proliferation of C2C12 myoblasts and its upstream signals: IGF-1-mediated PI3K/Akt and MAPKs pathways. Mol Cell Endocrinol. 450:83–93. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Iskender B, Izgi K, Sakalar C and Canatan H: Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: A way to harness hMSC cytokine expression via modulating PI3K/Akt pathway? Tumour Biol. 37:1967–1981. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y and Tamura K: Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. Ann Oncol. 25:1973–1979. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Liu C, Liu Z, Li X, Tang X, He J and Lu S: MicroRNA-1297 contributes to tumor growth of human breast cancer by targeting PTEN/PI3K/AKT signaling. Oncol Rep. 38:2435–2443. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2018
Volume 40 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Guan, J., Zhou, Y., Mao, F., Lin, Y., Shen, S., Zhang, Y., & Sun, Q. (2018). MicroRNA‑320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulin‑like growth factor 1 receptor. Oncology Reports, 40, 849-858. https://doi.org/10.3892/or.2018.6517
MLA
Guan, J., Zhou, Y., Mao, F., Lin, Y., Shen, S., Zhang, Y., Sun, Q."MicroRNA‑320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulin‑like growth factor 1 receptor". Oncology Reports 40.2 (2018): 849-858.
Chicago
Guan, J., Zhou, Y., Mao, F., Lin, Y., Shen, S., Zhang, Y., Sun, Q."MicroRNA‑320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulin‑like growth factor 1 receptor". Oncology Reports 40, no. 2 (2018): 849-858. https://doi.org/10.3892/or.2018.6517